Sushmi Dey

Stories by Sushmi Dey

Indian drug cos to benefit as US expedites generic clearances

Indian drug cos to benefit as US expedites generic clearances

Rediff.com   12 May 2014

Even smaller companies like Torrent Pharma and Alembic file five to 10 ANDAs every year.

Novartis-Glaxo deal signals pharma firms don't have it easy

Novartis-Glaxo deal signals pharma firms don't have it easy

Rediff.com   24 Apr 2014

Experts say despite it being a global deal, the transaction will have to undergo CCI scrutiny because of the scale of operations.

Novartis-GSK-Eli Lilly deal may affect Indian market

Novartis-GSK-Eli Lilly deal may affect Indian market

Rediff.com   23 Apr 2014

On Tuesday, Novartis agreed to buy GSK's oncology products business for $14.5 billion, while selling its vaccines business, excluding flu, to GSK for $7.1 billion.

ICAI to ban three auditors in Satyam case

ICAI to ban three auditors in Satyam case

Rediff.com   23 Apr 2014

ICAI has also imposed a fine of Rs 5 lakh on each of the three accused in Satyam case.

Ranbaxy buy in line with Sun's strategy

Ranbaxy buy in line with Sun's strategy

Rediff.com   17 Apr 2014

The company buys distressed assets across the globe and turns them around to not only add to its books but also its product pipeline and regions.

Regulatory pain for GSK's Crocin Advance

Regulatory pain for GSK's Crocin Advance

Rediff.com   28 Mar 2014

The NPPA letter was issued to GSK on Wednesday.

Consumers may have to pay more for insulin

Consumers may have to pay more for insulin

Rediff.com   21 Mar 2014

Apart from Wockhardt, only Biocon manufactures insulin analog indigenously.

24 private hospitals get showcause notices

24 private hospitals get showcause notices

Rediff.com   20 Mar 2014

What started as a mere payment delay seems to have grown into a tussle between the government and leading private hospitals, empanelled under the Central Government Health Scheme.

Why is Novartis likely to lose Tiamulin drug licence?

Why is Novartis likely to lose Tiamulin drug licence?

Rediff.com   19 Mar 2014

Legal experts and official sources said the alleged submission of fake documents can also lead to criminal charges against Novartis.

US regulator urges USV to probe staff for inaccurate data reporting

US regulator urges USV to probe staff for inaccurate data reporting

Rediff.com   5 Mar 2014

The US Food and Drug Administration has asked USV to probe employees who might have been responsible for inaccurate data reporting.

Why is DLF again under competition watchdog's scanner?

Why is DLF again under competition watchdog's scanner?

Rediff.com   4 Mar 2014

CCI has accused realty player DLF of preparing one-sided agreement with home buyers

Ranbaxy whistle-blower to talk on quality of Made-in-India drugs

Ranbaxy whistle-blower to talk on quality of Made-in-India drugs

Rediff.com   27 Feb 2014

Whistle-blower Dinesh Thakur will speak on Made-in-India drugs at an event in Washington.

Scanner on Novartis for giving 'fake' documents

Scanner on Novartis for giving 'fake' documents

Rediff.com   10 Feb 2014

Swiss drug maker Novartis might face tough action from the country's drug regulator for allegedly giving fake documents while seeking renewal of registration for Tiamulin Hydrogen Fumerate (80 per cent granules), sources said.

After ban on drug facilities, US regulator comes calling

After ban on drug facilities, US regulator comes calling

Rediff.com   10 Feb 2014

Margaret A Hamburg, the first commissioner of the US Food and Drug Administration (US FDA) to visit India officially, will meet heads of major domestic pharma companies such as Ranbaxy, Wockhardt, Cadila Healthcare and Lupin in New Delhi.

HCL sees wealth in health care

HCL sees wealth in health care

Rediff.com   3 Feb 2014

Formal announcement of venture into new segment on Thursday; group's entry timely, given the demand, say experts

Indian drug regulator threatens to ban Ranbaxy

Indian drug regulator threatens to ban Ranbaxy

Rediff.com   29 Jan 2014

A day after getting a show-cause notice from the Indian regulator, senior executives from Ranbaxy Laboratories approached the drug controller's office on Tuesday afternoon, it was learnt.

Drug regulator lets pharma firms fix own penalty

Drug regulator lets pharma firms fix own penalty

Rediff.com   20 Jan 2014

Even as the Supreme Court had recently dismissed the industry's plea against prices fixed by the regulator and its timely implementation, the National Pharmaceutical Pricing Authority has asked companies to pay the overcharged dues with 15 per cent interest.

After Ajay Devgn, Kamal Haasan approaches CCI

After Ajay Devgn, Kamal Haasan approaches CCI

Rediff.com   14 Jan 2014

Kamal Haasan has filed a complaint with the Competition Commission of India (CCI) against the Tamil Nadu Theatre Owners Association wifor restricting the release of his film Vishwaroopam in theatres last year.

Wockhardt's review petitions on drug pricing rejected

Wockhardt's review petitions on drug pricing rejected

Rediff.com   13 Jan 2014

Povidone iodine ointment and solutions are available in the market under various popular brands such as Betadine and Wokadine.

Nestle's cumin extract patent bid raises hackles

Nestle's cumin extract patent bid raises hackles

Rediff.com   8 Jan 2014

Company claims new use for kala jeera extract, provoking alarmed campaigners here and abroad; says reaction not based on facts.